Currently Viewing:
Currently Reading
Clinical Trial Participation Reduces Alcohol Intake, Improves HIV Outcomes in Women Regardless of Treatment Type
August 22, 2019 – Jaime Rosenberg
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Opioid Injection in Rural Areas Presents a Challenge to Ending HIV Epidemic in US
August 13, 2019 – Jaime Rosenberg
Researchers Say They Developed an Approach to Further Suppress HIV Infection
August 09, 2019 – Jaime Rosenberg
For Children Born With HIV, Medication Adherence, Viral Suppression Decreases With Age
August 06, 2019 – Jaime Rosenberg
What We're Reading: Pay-to-Play Clinical Trials; Acting on US Drug Import Plan; HIV Provider Shortage
August 06, 2019 – AJMC Staff
Among Elderly Patients With Cancer, Those With HIV Fare Worse Even After Adjusting for Treatment Variation
August 01, 2019 – Jaime Rosenberg
Top 5 AJMC® Articles of July 2019
July 31, 2019

Clinical Trial Participation Reduces Alcohol Intake, Improves HIV Outcomes in Women Regardless of Treatment Type

Jaime Rosenberg
Women participating in a randomized clinical trial were able to significantly reduce their alcohol intake regardless of medication assignment and subsequently improve rates of viral suppression.
For women with unhealthy alcohol use, participating in a randomized controlled trial to cut alcohol use also produces positive spillover effects on HIV outcomes, according to study findings.

For women who drink more than 7 drinks per week or more than 3 drinks per occasion, study participation helped them improve viral suppression. Typically, women are less likely to achieve viral suppression than men, and unhealthy alcohol use further widens this disparity by worsening medication adherence, thus lowering rates of viral suppression and escalating disease progression.

Interestingly, participating in the trial significantly reduced drinking habits regardless of medication assignment. Of the 194 women participating in the study, 96 took daily oral naltrexone and the other 98 took placebo. After 4 months, reductions in drinking were comparable, leading the researchers to suggest that nonmedication aspects of studies, such as repeated assessments and support from research staff, can be critical interventions for reducing drinking outside of studies.

“The fact that women receiving placebo did so well is striking,” expressed the researchers.

At the beginning of the study, all women met criteria for unhealthy alcohol use and 62% met criteria for alcohol use disorder. “Only about 50% of women reported ongoing unhealthy alcohol use at 4 months, and the proportion with unhealthy alcohol use continued to drop even after medication was stopped,” noted the researchers, adding that at 7 months, 64% of the women had reduced or quit drinking.

At first, naltrexone demonstrated a greater reduction in drinking compared with placebo; however, after 4 months, there was no difference between the 2 groups.

The behavior change also resulted in benefits to HIV outcomes. Approximately two-thirds (63%) of the women had viral suppression when they enrolled in the study between 2013 and 2016. After 7 months, 74% of the women who had reduced or quit drinking achieved viral suppression compared with 54% of those who did not cut down on their alcohol use.


Cook R, Zhou Z, Miguez M, et al. Reduction in drinking associated with improved clinical outcomes in women with HIV infection and unhealthy alcohol use: results from a randomized clinical trial of oral naltrexone versus placebo [published online July 10, 2019]. Alcohol Clin Exp Res. doi: 10.1111/acer.14130.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up